<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Pharmacotherapy based on <z:chebi fb="0" ids="6775">5-aminosalicylic acid</z:chebi> (<z:chebi fb="0" ids="6775">5-ASA</z:chebi>) is a preferred treatment for <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo>, but variable patient response to this therapy is observed </plain></SENT>
<SENT sid="1" pm="."><plain><z:mp ids='MP_0001845'>Inflammation</z:mp> can affect therapeutic outcomes by regulating the expression and activity of drug-metabolizing enzymes; its effect on <z:chebi fb="0" ids="6775">5-ASA</z:chebi> metabolism by the colonic arylamine N-acetyltransferase (NAT) enzyme isoforms is not firmly established </plain></SENT>
<SENT sid="2" pm="."><plain>We examined if <z:mp ids='MP_0001845'>inflammation</z:mp> affects the capacity for colonic <z:chebi fb="0" ids="6775">5-ASA</z:chebi> metabolism and NAT enzyme expression </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="6775">5-ASA</z:chebi> metabolism by colonic mucosal homogenates was directly measured with a novel fluorimetric rate assay </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="6775">5-ASA</z:chebi> metabolism reported by the assay was dependent on Ac-CoA, inhibited by alternative NAT substrates (<z:chebi fb="1" ids="6030">isoniazid</z:chebi>, p-aminobenzoylglutamate), and saturable with Km (<z:chebi fb="0" ids="6775">5-ASA</z:chebi>) = 5.8 Î¼M </plain></SENT>
<SENT sid="5" pm="."><plain>A mouse model of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:chebi fb="0" ids="34674">dextran sulfate</z:chebi> <z:chebi fb="199" ids="26708">sodium</z:chebi> (DSS) <z:hpo ids='HP_0002583'>colitis</z:hpo> caused pronounced <z:mp ids='MP_0001845'>inflammation</z:mp> in central and distal colon, and modest <z:mp ids='MP_0001845'>inflammation</z:mp> of proximal colon, defined by myeloperoxidase activity and histology </plain></SENT>
<SENT sid="6" pm="."><plain>DSS <z:hpo ids='HP_0002583'>colitis</z:hpo> reduced capacity for <z:chebi fb="0" ids="6775">5-ASA</z:chebi> metabolism in central and distal colon segments by 52 and 51%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Use of selective substrates of NAT isoforms to inhibit <z:chebi fb="0" ids="6775">5-ASA</z:chebi> metabolism suggested that mNAT2 mediated <z:chebi fb="0" ids="6775">5-ASA</z:chebi> metabolism in <z:mpath ids='MPATH_458'>normal</z:mpath> and <z:hpo ids='HP_0002583'>colitis</z:hpo> conditions </plain></SENT>
<SENT sid="8" pm="."><plain>Western blot and real-time RT-PCR identified that proximal and distal mucosa had a decreased mNAT2 protein-to-<z:chebi fb="2" ids="33699">mRNA</z:chebi> ratio after DSS </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, an <z:hpo ids='HP_0011009'>acute</z:hpo> colonic <z:mp ids='MP_0001845'>inflammation</z:mp> impairs the expression and function of mNAT2 enzyme, thereby diminishing the capacity for <z:chebi fb="0" ids="6775">5-ASA</z:chebi> metabolism by colonic mucosa </plain></SENT>
</text></document>